Commitments focus on advancing equitable access to artificial intelligence (AI) and vaccines, and catalyzing innovations that address women’s health

SEATTLE and DAKAR, Senegal, Oct. 10, 2023 /PRNewswire/ — A slate of new initiatives to support locally led innovation was announced today in Dakar by the Bill & Melinda Gates Foundation and its partners at the Grand Challenges Annual Meeting. The investments come with an urgent call for countries to step up funding to make the research and development (R&D) of health and development innovations easier and faster, and to make the next generation of scientific and technological breakthroughs relevant and accessible to all.

Data shows that while overall health R&D funding is increasing, only about 2% is directed toward diseases that affect the world’s poorest people. In 2020, the annual funding gap for product development targeting poverty-related and neglected diseases was estimated at US$2.6 billion.

"Over the past two decades, global investments in a pipeline of innovative solutions helped reduce childhood deaths under 5 by half," said Moussa Balde, Senegal’s minister for higher education, research and innovation. "But lifesaving innovations still take too long to reach those who need them and are not always designed with equity from the start. Grand Challenges Senegal continues to invest in the country’s brightest scientists and innovators, and we are pleased to be part of this global network of Grand Challenges partners investing in locally led solutions to ensure innovations, including in health, education, and agriculture, benefit everyone equally."

Launched in 2003, Grand Challenges, the foundation’s flagship innovation program, focuses attention and funding on pressing global health and development problems that affect the world’s poorest people, using open calls for proposals to crowdsource potential solutions.

In an address to the more than 1,400 scientists, policymakers, and donors attending the annual meeting, Bill Gates, co-chair of the Gates Foundation, called for the world to spend at least US$3 billion more every year on global health and development R&D in order to close the critical gaps in funding for neglected diseases.

"New health technologies have the potential to save millions of lives, but R&D funding is going in the wrong direction," said Gates. "Donors need to step up their commitments to ensure health innovations reach those who need them more quickly, so more lives can be saved."

Today, Gates announced that the foundation is investing US$30 million to support a new artificial intelligence (AI) platform in Africa. The platform will provide African scientists and innovators with the technical and operational support they need to turn promising ideas into scalable health and development solutions. It is a step towards ensuring the benefits of AI are relevant, affordable, and accessible to everyone—particularly those in low- and middle-income countries (LMICs)—and that these critical tools are developed safely, ethically, and equitably. The foundation will continue to work closely with technical partners and governments to further advance the platform and identify opportunities to jointly advance the use of AI for health and development.

Yesterday, the foundation also announced new investments aimed at expanding access to a novel mRNA vaccine manufacturing platform that gives countries, including Senegal and South Africa, the technology to develop and manufacture their own vaccines. mRNA technology is considered a potential game-changer for a range of infectious diseases, including tuberculosis, malaria, and Lassa fever, which disproportionately affect people in LMICs. This additional local vaccine manufacturing capacity will support LMICs to develop low-cost, high-quality vaccines that address their most urgent health priorities.

"What started as a single program funded by the Gates Foundation and its partners has grown into a family of initiatives and partnerships across national borders, fields of study, and sectors that catalyze research, products, and partnerships to save and improve the lives of the world’s most vulnerable people," said Kedest Tesfagiorgis, deputy director, global partnerships and Grand Challenges at the foundation. "Our community of brilliant innovators is proof that a great idea can come from anywhere and be supported by the funders, policymakers, and advocates needed to move ideas into the laboratory and, ultimately, to the people who can most benefit from them."

Grand Challenges is supported by the governments of India, China, Brazil, the United States, and Canada, as well as a growing number of countries in Africa, including Ethiopia, Rwanda, Senegal, and South Africa. Since 2003, partners have invested US$1.6 billion to support more than 3,800 projects in 118 countries—from new strategies to improve gut health in moms and children to reinventing the toilet for improved sanitation to reimagining drug discovery research for malaria, tuberculosis, and neglected tropical diseases. 

To further support scientists developing cutting-edge innovations in LMICs, the foundation and its partners also issued new calls for proposals in the following areas:

Equitable AI for health in LMICs. Building on a recent Grand Challenge (GC) to develop global health and development solutions in LMICs using AI-enabled large language models (LLMs), GC partners issued a request for proposals of up to US$5.5 million to help advance the development of robust, locally relevant, AI-empowered tools to expedite decision-making, policy pathways, and implementation by frontline health workers and policymakers. The call is led by GC Brazil, GC India, GC Ethiopia, GC Senegal, GC South Africa, and GC Africa, with support from GC Canada, the Patrick J. McGovern Foundation, the Pasteur Network, and the Gates Foundation. Women’s health R&D to unlock the potential of half the world’s population and unleash a powerful engine for progress. The Women’s Health Innovation Opportunity Map 2023 is a new report outlining 50 equitable, high-return opportunities across the R&D continuum to maximize research and innovation, investments, and global action in women’s health. To encourage innovations and ideas laid out in the Opportunity Map, the foundation announced a new request for proposals that will provide up to US$3.6 million in funding. Innovations in global health and development across other critical areas of need. The full list of new requests for proposals can be found here.

The 2023 Grand Challenges Annual Meeting in Dakar is hosted by the Global Grand Challenges network of partners and the government of Senegal, and sponsored by Grand Challenges Canada, the United States Agency for International Development, Wellcome, and the Bill & Melinda Gates Foundation.

About Grand Challenges

The Grand Challenges family of programs stems from a century-old idea that crowdsourcing solutions to a defined set of unsolved problems can spark innovation and accelerate progress. The Bill & Melinda Gates Foundation and its Grand Challenges funding partners first used Challenges—open requests for grant proposals—in 2003 to focus attention and effort on pressing global health and development problems for those most in need. Together, Grand Challenges partners have awarded US$1.6 billion across 3,800 grants to a diverse pool of problem solvers in 118 countries, while at the same time fostering a global innovation ecosystem in places where it will have the most impact. The foundation and its Grand Challenges partners will continue to launch RFPs to support innovators from around the world in tackling the hardest, most urgent Grand Challenges. To learn more, visit grandchallenges.org.

About the Bill & Melinda Gates Foundation

Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Mark Suzman, under the direction of Co-chairs Bill Gates and Melinda French Gates, and the board of trustees.

Media contact: [email protected]

Source : Gates Foundation Celebrates 20 Years of "Grand Challenges" With New Investments and a Call to Make R&D Breakthroughs Available More Quickly and Equitably

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

— STX-721 is characterized by high selectivity and a potentially best-in-class profile —

— Scorpion’s second program to enter clinical development this year —

— One of two EGFR programs being developed with Pierre Fabre Laboratories — 

BOSTON and CASTRES, France, Oct. 10, 2023 /PRNewswire/ — Scorpion Therapeutics, Inc. ("Scorpion"), a pioneering clinical-stage oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, and Pierre Fabre Laboratories today announced that the first patient has been dosed in a Phase 1/2 first-in-human dose escalation and expansion clinical trial evaluating STX-721, Scorpion’s highly differentiated, orally bioavailable, irreversible highly selective tyrosine kinase inhibitor ("TKI") targeting epidermal growth factor receptor ("EGFR") and ERBB2 (HER2) Exon 20 insertion ("ex20ins") mutations, well-known, clinically validated oncogenic drivers in non-small cell lung cancer ("NSCLC"). The Phase 1/2 clinical trial will evaluate STX-721 as a monotherapy in participants with locally advanced or metastatic NSCLC harboring EGFR ex20ins mutations.

NSCLC is the most common sub-type of lung cancer and various EGFR mutations are the most frequent drivers of NSCLC, occurring in up to 38% of tumors, depending on geography.[1],[2],[3] Of this population, up to 10% have ex20ins mutations.[4]

"We are excited to begin the clinical evaluation of STX-721, our mutant-selective EGFR ex20ins inhibitor with a potentially best-in-class profile, for the treatment of non-small cell lung cancer," said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion. "The initiation of our second clinical trial this year underscores our research team’s productivity and execution, as well as the confidence that Scorpion and Pierre Fabre Laboratories have in the quality, selectivity, and potential clinical differentiation of this compound. Based on preclinical data to-date, we believe that STX-721 is more selective and can provide a wider therapeutic window than other therapies currently on the market or in development and, as a result, has the potential to deliver superior efficacy to this highly underserved patient population." 

"We are pleased to see STX-721 enter the clinic, and the overall progress we’ve achieved since we announced the partnership with Scorpion six months ago," said Eric Ducournau, Chief Executive Officer of Pierre Fabre Labor­­­­­­atories. "Our two teams have been working closely on both of the EGFR candidates and we look forward to seeing how patients may benefit from this targeted therapy."

STX-721 is an oral treatment designed to be mutant-selective and optimized for tolerability and efficacy when compared to currently available commercial treatments. Existing therapeutic options face significant limitations that are associated with the inhibition of wild-type EGFR in healthy tissues, including serious adverse events often leading to dose reductions or interruptions. 

"STX-721 is a wild-type-sparing, oral inhibitor of EGFR ex20ins mutations with a compelling preclinical selectivity profile," said Michael Streit, M.D., Chief Medical Officer of Scorpion. "In this Phase 1/2 trial, we will aim to demonstrate how these unique qualities translate into a potentially best-in-class product profile that increases response rates as a result of its optimized design. We look forward to partnering with study investigators, as well as our colleagues at Pierre Fabre Laboratories, to evaluate STX-721 in patients with EGFR ex20ins-mutated NSCLC."

About STX-721 Phase 1/2 Trial

Scorpion’s Phase 1/2 clinical trial, in collaboration with Pierre Fabre Laboratories, is a multi-center, open-label study designed to evaluate the safety and tolerability of STX-721 in multiple ascending doses for patients with locally advanced or metastatic NSCLC driven by EGFR mutations. The goal of the trial is to characterize the safety profile of STX-721 and determine a maximum tolerated dose or a lower optimal-biologically active dose, if appropriate, as the recommended Phase 2 dose ("RP2D") as a monotherapy for NSCLC driven by EGFR exon20ins mutations. Once the RP2D is established, Scorpion intends to continue to evaluate the safety, tolerability and overall efficacy of STX-721. Secondary objectives for this Phase 1/2 trial include assessing the pharmacokinetic profile, pharmacodynamic effects and clinical response as measured by Response Evaluation Criteria In Solid Tumors ("RECIST") version 1.1. To learn more about the first-in-human trial of STX-721, please visit this page.

About Scorpion Therapeutics

Scorpion is a pioneering clinical-stage oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of patients with cancer, a strategy Scorpion refers to as Precision Oncology 2.0. Scorpion has built a proprietary and fully integrated platform of the most advanced technologies across cancer biology, medicinal chemistry, and data sciences, with the goal of consistently and rapidly creating exquisitely selective small molecule compounds against an unprecedented spectrum of targets. Scorpion aims to leverage its platform to advance a broad pipeline of wholly owned, optimized compounds across three target categories: best-in-class molecules targeting validated oncogene targets; first-in-class molecules for previously undruggable targets; and first-in-class molecules for novel cancer targets. For more information, visit www.scorpiontx.com.

About Pierre Fabre Laboratories

Pierre Fabre Laboratories is a leading French medical and beauty care company with over 4 decades of experience in innovation, development, manufacturing, and commercialization in oncology. The company dedicated about 80% of its R&D spendings to oncology in 2022 and has declared targeted therapies as its main R&D priority. Its current commercial portfolio in oncology covers colorectal, breast and lung cancers, melanoma, hematology, and pre-cancerous skin conditions like actinic keratosis. 

In 2022, Pierre Fabre Laboratories posted 2.7 billion euros in revenues, 69% of which came from international sales in 120 countries. Established in the South-West of France since its creation in 1962, the Group manufactures over 90% of its products in France and employs some 9,600 people worldwide. The company is 86%-owned by the Pierre Fabre Foundation, a government-recognized public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan. Pierre Fabre Laboratories’ sustainability policy has been assessed by the independent AFNOR Certification body at the "Exemplary" level of its CSR label (ISO 26 000 standard for sustainable development). 

Further information about Pierre Fabre Laboratories can be found at www.pierre-fabre.com, @PierreFabre.

For Scorpion Therapeutics:

Media Contact:
Ravi Moorthy
Scorpion Therapeutics, Inc.
[email protected]

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
[email protected]

For Pierre Fabre Laboratories:

Media Contact:
Laure Sgandurra
Pierre Fabre Laboratories
[email protected] 

[1] The Prevalence of EGFR Mutation in Patients with Non-Small Cell Lung Cancer, Oncotarget, October 2016
[2] EGFR Mutation Incidence in Non-Small Cell Lung Cancer, J Cancer Res., August 2015
[3] Molecular Epidemiology of EGFR Mutations in Asian Patients, PLoS ONE, November 2015
[4] EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives, Biomarker Research, April 2022

Source : Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

STAMFORD, Conn., Oct. 10, 2023 /PRNewswire/ — Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, today announced that it has successfully completed the grid connection of its inaugural solar storage project on September 26th in Ningbo, Zhejiang Province, China. This project has a capacity of 0.6 MW/1.2 MWh, operates behind the meter and is backed by a private long-term power purchase agreement (PPA) with a local off-taker. It has been strategically designed to yield high returns through daily price arbitration, emphasizing the Company’s commitment to sustainable and financially responsible energy solutions.

Yumin Liu, CEO of Emeren Group commented, "We are absolutely thrilled to witness the successful operation of our inaugural solar energy storage project in China. This project marks a major milestone and represents a defining chapter in our journey toward becoming a leading global renewable energy company. In addition to this accomplishment, we currently have a portfolio of projects in the planning and execution phases in China, including several Commercial and Industrial (C&I) sized storage projects that are currently under construction. As part of our strategic vision, we plan to further expand our storage portfolio under our light IPP strategy. Furthermore, we remain steadfast in our commitment to executing our storage business strategies, solidifying our dedication to sustainable and innovative energy solutions."

About Emeren Group Ltd

Emeren Group Ltd (NYSE: SOL) is a leading global solar project developer, owner, and operator with a pipeline of projects and IPP assets totaling over 3 GW, as well as a storage pipeline of over 6 GWh across Europe, North America, and Asia. The Company focuses on solar power project development, construction management and project financing services with local professional teams across multiple countries. For more information, go to www.emeren.com.

Source : Emeren Group Announces Inaugural Solar Energy Storage Project in China

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SHENZHEN, China, Oct. 10, 2023 /PRNewswire/ — In the digital age, the impact of data is becoming increasingly profound. By the end of 2022, a myriad of big data artificial intelligence models had emerged with varying degrees of quality. The effectiveness of these models highly depends on the quality of the input data, thereby imposing higher standards for data quality. However, people’s understanding of the essence of data is still at a relatively primitive stage. This has led to three major issues in existing data processing techniques: The first issue is the ignorance of the inherent uncertainty present in data; the second is a lack of effective methods for predictions; and the third is overlooking the bias introduced by the human-data relationship.

To address these issues, on October 9, 2023, Mongoose Think Tank officially launched TDRU (Tools of Data Reconstruction on Uncertainty) – a tool based on the principle of uncertainty that aims to solve the aforementioned problems through data reconstruction.

Theoretical Background of TDRU
Over time, Mongoose Think Tank has researched the sources of uncertainty extensively. In the field of data science, in his 2023 article "Uncertainty and Data Reconstruction" published in the Chinese Banking Industry magazine, Mongoose Think Tank’s Academic Committee Chairman Zhu Xiaohuang deeply discussed the issue of uncertainty in data. Zhu believes the essence of the world is uncertainty, causing randomness in human society and behavior. As data reflects the objective world and human behavior, it also carries uncertainty.

In his article "A Human-Centric Perspective on Data", Mongoose Think Tank’s expert Hu Benli argues that all data subjectively reflects humans’ perspective on the objective world. He describes an ongoing cycle where humans generate large amounts of data while simultaneously being influenced by it. This inherent bias in data, Hu states, provides the fundamental rationale for needing data governance.

To address these issues of uncertainty and human-data relationships, Mongoose Think Tank have designed and proposed a method for reconstructing data based on these principles. Our approach categorizes data into types including historical data and marginal data, natural data and behavioral data, as well as deterministic data and random data. Building upon the elimination of random data, it assigns different adjustment parameters and weights to different types of data. Subsequently, Mongoose Think Tank applied and refined this methodology in real-world scenarios, culminating in the development of TDRU (Tools for Data Reconstruction on Uncertainty) version 1.0.

Introduction to TDRU
TDRU operates through six core processes, two sets of parameters, and seven collaborative tools. It can address both types of problems arising from uncertainty and adjust biases between humans and data. TDRU is not just a methodology but also practical as a tool. Its uniqueness lies in being the first tool specifically designed to tackle issues of data uncertainty, marking a significant advance over existing data processing methods. TDRU can be widely applied to various scenarios for predicting and measuring the likelihood of future events, making it suitable for major financial institutions, commercial enterprises, and global economic forecasts by world organizations. Additionally, Mongoose Think Tank are in the process of developing a data reconstruction intelligent assistant software that integrates TDRU with large language models.

TDRU is a foundational data tool based on the principle of uncertainty, primarily aimed at the pre-analytical stage of data analysis, namely data cleansing. Due to its foundational nature, the range of its applications is extensive, covering sectors such as economics, finance, and energy, among many others that require heavy use of data for modeling, analysis, and future prediction. Consequently, its client base is diverse, encompassing enterprises, financial institutions, and international organizations across the globe that need to employ data for forecasting. Additionally, due to the high correlation between uncertainty and risk management, TDRU offers unique value in the field of risk management. Overall, TDRU is not only a multi-functional and cross-sectoral methodology with international applicability but also a potent tool capable of solving a myriad of data quality issues, thereby enhancing the accuracy of future predictions.

TDRU Application Cases
Mongoose Think Tank applied TDRU to a personal credit scorecard of a listed bank. From the perspective of model evaluation parameters, before using TDRU, the model’s AUC (Area Under Curve, which measures the authenticity of the detection method; the closer AUC is to 1.0, the higher the authenticity; at 0.5, it has the lowest authenticity and no application value) was approximately 0.84, and KS (Kolmogorov-Smirnov, which evaluates the model’s risk differentiation ability; the greater the cumulative difference between good and bad samples, the greater the KS value and the stronger the risk differentiation ability of the model) was about 0.57. After using TDRU, the AUC increased to 0.88, and KS increased to 0.59. Importantly, these effects have been corroborated across multiple product lines.

Future
Currently, TDRU Version 1.0 has matured into a valuable tool for applications in macroeconomic forecasting, risk profiling and more. It has already obtained a software copyright and submitted an application for a patent.

Today, Mongoose Think Tank sincerely present this practical tool to the community at large, hoping to collaborate with various parties to expand the boundaries and possibilities of TDRU. Currently, Mongoose Think Tank can provide corresponding services related to TDRU, including consultation, training, and data processing. Mongoose Think Tank welcome inquiries from data enterprises, financial institutions, consulting firms, or any interested organizations. Please stay tuned for the future launch of TDRU Intelligent Assistant.

Company：Shenzhen Mongoose Consulting Co., Ltd.
Contact Person: Sun Wei
Email: [email protected]
Website: www.mongoose-report.com
Telephone: 0755-82713326 
City: Shenzhen

Source : TDRU Grand Release: Unveiling the Uncertainty Data Revolution

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SHENZHEN, China, Oct. 10, 2023 /PRNewswire/ — RoboSense, a global leader in the LiDAR and perception solutions market, proudly announces that it delivered over 20,000 units of automotive LiDAR in August 2023. Since the unveiling of the new era of global automotive industry intelligence at the Auto Shanghai 2023 in April, RoboSense has reached a new pinnacle in mass production, breaking the domestic record for monthly LiDAR shipments in the automotive sector.

RoboSense M Series LiDAR Monthly Sales Over 20,000 Units in August 2023.

Having achieved a milestone of nearly 10,000 units in June, RoboSense accomplished an extraordinary feat in August by doubling its monthly sales, exceeding 20,000 units. This achievement signifies a remarkable accomplishment, with monthly sales surpassing half of the total sales for the entire previous year.

The milestone signifies not only the scaling of LiDAR production capacity but also mirrors the global automotive industry’s commitment to intelligent transformation.

RoboSense acknowledges that this achievement is indebted to the extensive collaboration with a diverse range of automotive companies and Tier 1 clients, as well as the enthusiastic embrace of intelligent automotive features by consumers worldwide.

As of the end of August 2023, RoboSense has contributed to the successful mass production of 14 vehicle models, resulting in monthly sales exceeding 20,000 units of ADAS LiDAR.

Post-August, RoboSense remains committed to supporting the gradual mass production and delivery phases of several vehicle models. The company is poised to continue its efforts towards breaking delivery records once again.

Since its establishment, RoboSense has been customer-centric and consistently driving mass production and application of perception solutions to became one of the leading global players in the industry.

RoboSense remains unwavering in its commitment to its core values of innovation, perfection, simplicity, and pragmatism. Leveraging its multidimensional advantages in LiDAR technology innovation, product strength, market performance, and manufacturing capacity, RoboSense continues to drive mass production of intelligent driving solutions, providing people with a smarter, safer, and more reliable driving experience.

About RoboSense

Founded in 2014, RoboSense stands as a global leader in the LiDAR and perception solutions market. Its mission is to make the world safer and smarter by endowing automobiles and robots with perception capabilities superior to human eyes. With a customer-centric technology and highly iterative product development strategy, to provide the market with various Smart LiDAR perception system solutions.

Source : RoboSense Achieves Monthly Sales Volume of LiDAR for ADAS Over 20,000 Units

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Statement by Qatar Central Bank

DOHA, Qatar, Oct. 10, 2023 /PRNewswire/ — In line with the financial sector strategy and the financial technology (Fintech) strategy, and based on Qatar Central Bank’s permanent endeavor to regulate and develop the financial sector in the country, Qatar Central Bank issued instructions for the Loan-Based Crowdfunding Regulation, for the purpose of licensing and regulating (Loan-Based Crowdfunding activities and services in Qatar).

Qatar Central Bank Announces that all companies wishing to work in this field must apply to obtain the necessary license from QCB.

Loan-based crowdfunding platforms are considered innovative financial platforms that enable borrowers in need of financing to communicate with various investors and obtain short-term financing. Borrowers, such as SMEs, who find it difficult to access traditional bank loans, can obtain the financing necessary for growth of their business and overcome the challenges that they may face with the expansion of their projects. Loan-based crowdfunding platforms represent an important opportunity for investors to diversify their investments and participate in supporting SMEs.

Qatar Central Bank is keen to provide effective and valuable initiatives that help create an environment conducive to the growth of the financial technology sector in the country, as these platforms support the development of the financial sector and enhance the transparency, efficiency and ease of the borrowing process

Qatar Central Bank also stated that the instructions are available on QCB’s website.

Source : Qatar Central Bank issues instructions for the Loan-Based Crowdfunding Regulation

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

HONG KONG, Oct. 10, 2023 /PRNewswire/ — JS Global Lifestyle Company Limited (HKEx: 1691.HK) ("JS Global" or the "Group"), a world-leading small home appliance group with three major brands: Shark, Ninja and Joyoung, is pleased to announce that its subsidiary, JS Global Trading HK Limited, has entered into strategic cooperation with Concepcion Industrial Corporation ("CIC") for the exclusive distribution of "Shark" and "Ninja" branded products in the Philippines.

Shark and Ninja are globally recognized brands that offer 5-star lifestyle solutions to consumers around the world through innovative home appliance products. JS Global believes that the combined strengths of CIC and JS Global APAC will not only bring Shark and Ninja’s innovative and customer-centric products to Filipino consumers, but also open up new opportunities for the Shark and Ninja brands. It also marks a major step in the Group’s commitment to expanding into APAC markets and capturing greater market share.

The introduction of Shark and Ninja branded products into the Philippine market is poised to revolutionize consumers’ approach to home maintenance and cooking. Covering three essential aspects of daily life – hair styling, kitchen chores, and home cleaning – the upcoming product range offers innovative technology and user-friendly design. Designed to elevate the overall home experience, these products promise to improve convenience and efficiency in Filipino homes.

About JS Global

JS Global Lifestyle Company Limited is a world-leading group small home appliance group. It primarily operates three major brands: Shark, Ninja and Joyoung. The Company’s success is centered around its deep understanding of consumer needs, and is built on its strong product innovation and design capabilities powered by a global R&D platform, marketing strengths that drive high brand engagement, and omni-channel distribution coverage with high penetration.

JS Global Trading HK Limited holds the exclusive legal rights to the trademarks for the brand names "Shark" and "Ninja" in connection with the licensed products in the APAC region. It is a company incorporated in Hong Kong and is a wholly owned subsidiary of JS Global Lifestyle Company Limited.

About CIC

Concepcion Industrial Corporation (CIC) is the leading home and building & industrial solutions provider in the Philippines. With a history spanning over 60 years, CIC has established itself as a trusted name in the industry, dedicated to improving the lives of Filipino consumers through innovative and reliable products.

Grace Liu, [email protected] 

Source : JS Global Joins Forces with Concepcion Industrial Corporation to Bring Innovative Home Appliances to the Philippines

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network